Tatjana Rundek

TL;DR: Although IMT has been suggested to represent an important risk marker, according to the current evidence it does not fulfill the characteristics of an accepted risk factor and will help to improve the power of randomized clinical trials incorporating IMT measurements and to facilitate the merging of large databases for meta-analyses.

TL;DR: This updated consensus document delineates further criteria to distinguish early atherosclerotic plaque formation from thickening of IMT and recommends against serial monitoring in individual patients.

TL;DR: The addition of common CIMT measurements to the Framingham Risk Score was associated with small improvement in 10-year risk prediction of first-time myocardial infarction or stroke, but this improvement is unlikely to be of clinical importance.

TL;DR: A multiancestry genome-wide-association meta-analysis and discovered 22 new stroke risk loci, indicating mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets.

TL;DR: The consensus concludes that there is no need to ‘treat IMT values’ nor to monitor IMTvalues in individual patients apart from few exceptions and that IMT does not fulfill the characteristics of an accepted risk factor.